Brief: Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response
20/11/2025 21:38
Nov 20 (Reuters) - Pasithea Therapeutics Corp KTTA.O: PASITHEA THERAPEUTICS ANNOUNCES POSITIVE PHASE 1 DATA INCLUDING PARTIAL RESPONSE, DEMONSTRATING MONOTHERAPY CLINICAL ACTIVITY AND FAVORABLE SAFETY PROFILE FOR PAS-004 IN ADVANCED CANCER STUDY PASITHEA THERAPEUTICS CORP: PAS-004 HAS BEEN WELL-TOLERATED WITH ALL TREATMENT-RELATED ADVERSE EVENTS GRADE 1 OR 2 Source text: ID:nGNX9T4V3D Further company coverage: KTTA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pasithea Therapeutics
See all newsPasithea Therapeutics Corp reports results for the quarter ended June 30 - Earnings Summary
Pasithea Therapeutics Corp expected to post a loss of 16 cents a share - Earnings Preview
Brief: Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data
Brief: Pasithea Therapeutics Announces Closing Of $60 Million Public Offering Of Common Stock
Pasithea Therapeutics jumps after $60 million public offering announcement